PURPOSE: Quantitation of β-tubulin isotype expression in taxane resistant human tumor tissue has been difficult to achieve because of the limited availability of validated antibodies. Here we present a label-free MS method to quantitate relative expression levels of β-tubulin isotypes. EXPERIMENTAL DESIGN: Using isotype-specific reporter peptides, we determined relative β-tubulin isotype expression levels in human lung tumor tissue. RESULTS: Four reporter peptides were chosen to quantitate the βI/βII, βIV, βIII, and βV tubulin isotypes. These peptides were validated using human cancer cell lines. The label-free method was then used to determine β-tubulin isotype expression in nine human lung tumor samples, which had been described as high or low βIII-tubulin expressing using immunohistochemistry. It was found that βI/βII (accounting for 18.7-65.7% of total β-tubulin) and βIVa/βIVb (26.3-79.1%) were the most abundant isotypes and that the βIII (0-8.9%) and βV (1.0-10.4%) were less abundant in the tissue. We also categorized the samples as high or low βIII-tubulin expressing. CONCLUSION AND CLINICAL RELEVANCE: With this method we can determine the relative expression levels of β-tubulin isotypes in human tumor tissue. This method will facilitate studies assessing the use of tubulin isotypes as biomarkers of taxane resistance.
PURPOSE: Quantitation of β-tubulin isotype expression in taxane resistant humantumor tissue has been difficult to achieve because of the limited availability of validated antibodies. Here we present a label-free MS method to quantitate relative expression levels of β-tubulin isotypes. EXPERIMENTAL DESIGN: Using isotype-specific reporter peptides, we determined relative β-tubulin isotype expression levels in humanlung tumor tissue. RESULTS: Four reporter peptides were chosen to quantitate the βI/βII, βIV, βIII, and βV tubulin isotypes. These peptides were validated using humancancer cell lines. The label-free method was then used to determine β-tubulin isotype expression in nine humanlung tumor samples, which had been described as high or low βIII-tubulin expressing using immunohistochemistry. It was found that βI/βII (accounting for 18.7-65.7% of total β-tubulin) and βIVa/βIVb (26.3-79.1%) were the most abundant isotypes and that the βIII (0-8.9%) and βV (1.0-10.4%) were less abundant in the tissue. We also categorized the samples as high or low βIII-tubulin expressing. CONCLUSION AND CLINICAL RELEVANCE: With this method we can determine the relative expression levels of β-tubulin isotypes in humantumor tissue. This method will facilitate studies assessing the use of tubulin isotypes as biomarkers of taxane resistance.
Authors: Pascal Verdier-Pinard; Shohreh Shahabi; Fang Wang; Berta Burd; Hui Xiao; Gary L Goldberg; George A Orr; Susan Band Horwitz Journal: Biochemistry Date: 2005-12-06 Impact factor: 3.162
Authors: Hao Hu; Xi Gu; Liang-Jiao Xue; Prashant S Swamy; Scott A Harding; Chung-Jui Tsai Journal: Front Plant Sci Date: 2016-10-13 Impact factor: 5.753
Authors: Prashant S Swamy; Hao Hu; Sivakumar Pattathil; Victoria J Maloney; Hui Xiao; Liang-Jiao Xue; Jeng-Der Chung; Virgil E Johnson; Yingying Zhu; Gary F Peter; Michael G Hahn; Shawn D Mansfield; Scott A Harding; Chung-Jui Tsai Journal: J Exp Bot Date: 2015-08-05 Impact factor: 6.992